Benitec Biopharma Inc. (NASDAQ: BNTC) reported third quarter 2026 financial results and provided updates on its BB-301 clinical development program for Oculopharyngeal Muscular Dystrophy.

The company reported a net loss of $11.9 million, or $0.24 per share, for the quarter ended March 31, 2026, compared to a net loss of $14.5 million, or $0.38 per share, in the same period last year. Total expenses decreased to $13.6 million from $15.3 million year-over-year.

Research and development expenses were $6.3 million, compared to $6.5 million in the prior year quarter. General and administrative expenses decreased to $7.3 million from $8.8 million. As of March 31, 2026, the company held $184.8 million in cash and cash equivalents.

In clinical developments, Benitec presented interim results from its BB-301 Phase 1b/2a study at the Muscular Dystrophy Association Clinical and Scientific Conference in March. The data showed responses to low dose BB-301 at 12-month and 24-month follow-ups, and improvements with high dose BB-301 at three months post-treatment.

All six patients in Cohort 1 completed the 12-month follow-up period, while the first two patients in Cohort 2 received high dose treatment. The company reported no treatment-related severe adverse events.

BB-301 interim results were selected for oral presentation at the American Society of Gene and Cell Therapy Annual Meeting on May 15. Benitec plans to engage with the FDA mid-year regarding pivotal study design and expects to provide updated interim results in the second half of 2026.

The information is based on a company press release statement.